The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents

Journal of the American College of Nutrition

Volumn 22, Issue 5, 2003, Pages 357-362

  Zhi, Jianguo ^a   Moore, Rema ^a   Kanitra, Linda ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Adolescents; Dietary fat inhibition; Mineral absorption; Orlistat

Indexed keywords

CALCIUM; COPPER; IRON; MAGNESIUM; MINERAL; PHOSPHORUS; PLACEBO; TETRAHYDROLIPSTATIN; ZINC;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CALORIC INTAKE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; ENERGY BALANCE; FAT INTAKE; FEMALE; HUMAN; INTESTINE ABSORPTION; LIPID ABSORPTION; MALE; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; URINARY EXCRETION;

ADOLESCENT; ANTI-OBESITY AGENTS; CHILD; DIETARY FATS; DOUBLE-BLIND METHOD; ELECTROLYTES; ENZYME INHIBITORS; FECES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL ABSORPTION; LACTONES; MALE; MINERALS; OBESITY;

EID: 0141988881     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2003.10719318     Document Type: Article

References (14)

1. Strauss RS, Pollack HA: Epidemic increase in childhood overweight, 1986-1998. JAMA 286:2845-2848, 2001.
2. Styne DM: Childhood and adolescent obesity: Prevalence and significance. Pediatr Clin North Am 48:823-854, 2001.
3. Deckelbaum RJ, Williams CL: Childhood obesity: the health issue. Obes Res 4(Suppl):239S-243S, 2001.
4. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH: Retrospective population-based analysis of the doseresponse (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56:82-85, 1994.
5. Henning SJ: Functional development of the gastrointestinal tract. In Johnson LR, Christensen J et al. (eds): “Physiology of the Gastrointestinal Tract,” 2nd ed, vol 1. New York: Raven Press, pp 285-300, 1987.
6. Pace DG, Blotner S, Guerciolini R: Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr 131:1694-1699, 2001.
7. Cummings JH, Jenkins DJ, Wiggins HS: Measurement of the mean transit time of dietary residue through the human gut. Gut 17:210-218, 1976.
8. Andersson H, Navert B, Bingham SA, Englyst HN, Cummings JH: The effects of breads containing similar amounts of phytate but different amounts of wheat bran on calcium, zinc and iron balance in man. Brit J Nutr 50:503-510, 1983.
9. Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN: Digestion and physiological properties of resistant starch in the human large bowel. Brit J Nutr 75:733-747, 1996.
10. Food and Nutrition Board: “Dietary Reference Intakes: Elements.” Washington DC: National Academy Press, 2001.
11. Schelkop GM, Milne DB: Wet microwave digestion of diet and fecal samples for inductively coupled plasma analysis. Anal Chem 60:2060-2062, 1988.
12. Van de Kramer JH, et al.: Titrimetri. J Biol Chem 177:347, 1949.
13. Gotfredsen A, Westergren Hendel H, Andersen T: Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 25:1154-1160, 2001.
14. Zhi J, Mulligan TE, Hauptman JB: Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 39:41-46, 1999.